OKI, vials, 150ml

Composition

Active ingredient:

ketoprofen lysine salt 16 mg;

Auxiliary substances:

glycerol — 200 mg;

ethanol — 0.05 ml;

methyl-p-hydroxybenzoate — 1.5 mg;

peppermint flavoring — 3 mg;

menthol — 0.7 mg;

sodium saccharin — 2 mg;

the”Certosa Verde” (green diamond) — 0.16 mg;

sodium hydrogen phosphate — 0,022 g;

distilled water — 1 ml;

Pharmacological action

OKI has anti-inflammatory, analgesic and antipyretic effects. By inhibiting COX-1 and -2, it inhibits PG synthesis. It has anti-radikinin activity, stabilizes lysosomal membranes and delays the release of enzymes from them that contribute to tissue destruction in chronic inflammation. Reduces the release of cytokines, inhibits the activity of neutrophils.

Reduces morning stiffness and swelling of the joints, increases the amount of movement.

Ketoprofen lysine salt, unlike ketoprofen, is a rapidly soluble molecule with a neutral pH and almost does not irritate

the gastrointestinal tract.

Suction. Administered orally, ketoprofen is rapidly and fairly fully absorbed from the gastrointestinal tract, its bioavailability is about 80%. Cmax in plasma when taken orally is noted in 0.5-2 hours, its value directly depends on the dose taken; after rectal use, Tmax is 45-60 minutes. CSS of ketoprofen is reached 24 hours after the start of its regular intake.

Distribution. Up to 99% of absorbed ketoprofen binds to plasma proteins, mainly albumin. Vd — 0.1–0.2 l / kg. It easily passes through histohematic barriers and is distributed in tissues and organs. Ketoprofen penetrates well into synovial fluid and connective tissues. Although the concentration of ketoprofen in synovial fluid is slightly lower than in plasma, it is more stable (persists up to 30 hours).

Metabolism. Ketoprofen is mainly metabolized in the liver, where it undergoes glucuronidation to form esters with glucuronic acid.

After using 160 mg of ketoprofen lysine salt in dosage form solution for topical application, the plasma concentration of ketoprofen is low-less than 400 ng / ml-and, therefore, insufficient for a pronounced systemic pharmacological effect.

Indications

• angina;
• laryngitis;
• pharyngitis;
• tonsillitis;
• stomatitis;
• gingivitis;
• glossitis;
• aphthae;
• paradontopathy;
• chronic paradontosis;
• dental manipulations (as an analgesic).

Use during pregnancy and lactation

As with other NSAIDs, AKI should not be used in the third trimester of pregnancy.

The use of the drug in the first and second trimester should be carefully monitored by the attending physician.

Breast-feeding should be discontinued when using the drug.

Contraindications

• hypersensitivity (including to other NSAIDs);
• aspirin asthma.

With caution:  peptic ulcer of the stomach and duodenum (exacerbation); ulcerative colitis (exacerbation); Crohn’s disease; diverticulitis; peptic ulcer; hemophilia and other blood clotting disorders; chronic renal failure; childhood (up to 6 years); pregnancy (III trimester); lactation period.

Side effects

Allergic reactions. If the drug is swallowed, systemic side effects may occur.

Interaction

Concomitant use with acetylsalicylic acid or other NSAIDs is not recommended.

When anticoagulants, diphenylhydantoin or sulfonamides are used simultaneously, their dosages should be reduced.

How to take, course of use and dosage

Locally. 2 rinses per day,10 ml of OKI solution (5 injections) per 1 dose.

The solution of 5 injections should be diluted in a cup attached to the package, half filled with drinking water.

By pressing the dispenser-injector located in the upper part of the bottle, the patient receives 1 injection — 2 ml of the OKI solution.

Accidental ingestion of the rinse solution does not lead to serious consequences, since a single dose of rinse contains 160 mg of ketoprofen lysine salt, which corresponds to the dose intended for oral use.

Adolescents over 12 years of age should use no more than 3 injections per cup.

Overdose

No data available.

Special instructions

During treatment, it is necessary to monitor the picture of peripheral blood and the functional state of the liver and kidneys.

If it is necessary to determine 17-ketosteroids, the drug should be discontinued 48 hours before the study.

Taking ketoprofen may mask the signs of an infectious disease.

In case of impaired renal and hepatic function, dose reduction and careful monitoring are necessary. The use of ketoprofen in patients suffering from bronchial asthma can lead to an attack of bronchial asthma.

Women planning pregnancy should refrain from taking the drug, as the likelihood of egg implantation may decrease.

Influence on the ability to drive vehicles and manage mechanisms.

During the period of using the drug, you should refrain from potentially dangerous activities related to the need for concentration of attention and rapid psychomotor reactions.

Product form

solution for topical application

Storage conditions

The drug should be stored out of the reach of children at a temperature not exceeding 25°C.

Shelf

life is 2 years.

Active ingredient

Ketoprofen

Dosage form

solution for topical application

Description

Pregnant women as prescribed by a doctor, Nursing mothers as prescribed by a doctor, For adults, Children as prescribed by a doctor

Indications

Tonsillitis, Periodontal Disease, Laryngitis, Stomatitis, Gum Disease, Sore Throat, Cold, Pharyngitis